NASDAQ
LEGN
Last Price
US $25.67
KEY FIGURES
MKT CAP
$4.7B
EPS
TTM
$-1.35
PEG
TTM
N/M
P/E
TTM
N/M
P/S
TTM
4.16x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Legend Biotech Corporation cash flow to debt ratio of -24.28% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Legend Biotech Corporation's free cash flow has decreased 6.26% from $-158.14M last year to $-168.04M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Legend Biotech Corporation's debt to equity ratio is 0.40, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Legend Biotech Corporation's debt has increased relative to shareholder equity from 0.34 last year to 0.40 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Legend Biotech Corporation has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Legend Biotech Corporation earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Legend Biotech Corporation's profit margin has increased (-22.16%) in the last year from -28.22% to -21.97%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Legend Biotech Corporation's short-term assets of $1.25G exceed its short-term liabilities of $636.40M
Decreasing performance - ROA.
Legend Biotech Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Legend Biotech Corporation's return on equity of -24.91%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Legend Biotech Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Legend Biotech Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Legend Biotech Corporation has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Legend Biotech Corporation has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Legend Biotech Corporation's yearly earnings has decreased 67.66% since last year from $-177.03M to $-296.80M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Legend Biotech Corporation's yearly revenue has increased 64.47% since last year from $627.24M to $1.03G, signaling increasing performance
Decreasing performance - ROIC.
ROIC -9.95% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Legend Biotech Corporation's 3-year revenue CAGR of 106.41% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Legend Biotech Corporation had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Legend Biotech Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Legend Biotech Corporation has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Legend Biotech Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Legend Biotech Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Legend Biotech Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Legend Biotech Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Legend Biotech Corporation has a price-to-book ratio of 4.90x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Legend Biotech Corporation has a price-to-sales ratio of 4.16x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-24.91%
Return on equity
ROIC: -9.95%
Valuation History
-19.9X
Price to Earnings
EV/EBITDA: -26.2X
Cash flow
Profit margin
68.83%
(FY vs FY)
EBITDA Y/Y
5.12%
(FY vs FY)
Cash flow Y/Y
8.55%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $25.67
—
Default assumptions
EBITDA Multiple
Fair Value
Market $25.67
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.